# Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations

> **NCT07670156** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Lisa Satter** · enrollment: 30 (estimated)

## Conditions studied

- JAK1 GOF
- STAT1 GOF
- STAT3 GOF
- STAT5B GOF
- STAT6 GOF

## Interventions

- **DRUG:** Upadacitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07670156
- **Lead sponsor:** Lisa Satter
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2028-08
- **Final completion:** 2028-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-09-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07670156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07670156, "Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07670156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*